Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Breaking & Recent News argenx SE ARGX

argenx SE is an immunology company. It is engaged in the business of developing a pipeline of differentiated antibody-based therapies for the treatment of severe autoimmune diseases and cancer. The group has partnered with academic researchers through its Immunology Innovation Program (IIP) and aims to translate immunology breakthroughs into a portfolio of novel antibody-based medicines. argenx developed and is commercializing the neonatal Fc receptor (FcRn) blocker in the U.S., Japan, and the EU. Its product pipeline includes product candidates such as ARGX-117, ARGX-118, ARGX-115, ARGX-116, and others.


Recent & Breaking News (NDAQ:ARGX)

argenx reports first quarter 2018 financial results and provides business update

GlobeNewswire May 9, 2018

argenx to receive third preclinical milestone payment from collaboration with LEO Pharma - Milestone associated with CTA approval for ARGX-112

GlobeNewswire April 12, 2018

argenx appoints Keith Woods as Chief Operating Officer

GlobeNewswire April 9, 2018

Earnings Scheduled For April 2, 2018

Benzinga.com  April 2, 2018

17 Stocks Moving In Monday's Pre-Market Session

Benzinga.com  March 26, 2018

5 Stocks To Watch For March 26, 2018

Benzinga.com  March 26, 2018

argenx announces orphan drug designation for ARGX-113 for the treatment of myasthenia gravis in Europe

GlobeNewswire March 26, 2018

argenx reports fourth quarter business update and full year 2017 financial results

GlobeNewswire March 1, 2018

7 Big Companies That Could Tap The IPO Markets In 2018

Benzinga.com  February 22, 2018

argenx announces closing of U.S. public offering for gross proceeds of approximately $266 million

GlobeNewswire December 18, 2017

Mid-Morning Market Update: Markets Rise; Disney To Buy Fox In $52 Billion Deal

Benzinga.com  December 14, 2017

argenx raises approximately $231 million in gross proceeds in an upsized U.S. public offering

GlobeNewswire December 13, 2017

11 Biotech Stocks Moving From ASH 2017

Benzinga.com  December 11, 2017

argenx announces launch of proposed public offering in the United States

GlobeNewswire December 11, 2017

Mid-Afternoon Market Update: NASDAQ Up 0.5%; bluebird bio Shares Spike Higher

Benzinga.com  December 11, 2017

Mid-Morning Market Update: Markets Edge Higher; 3M To Sell Communication Markets Division For $900M

Benzinga.com  December 11, 2017

argenx to provide updates on Phase 1/2 clinical trials of ARGX-110 in Acute Myeloid Leukemia and Cutaneous T-Cell Lymphoma during American Society of Hematology Annual Meeting

GlobeNewswire December 11, 2017

argenx reports positive topline results from Phase 2 proof-of-concept trial of ARGX-113 (efgartigimod) in generalized myasthenia gravis

GlobeNewswire December 11, 2017

argenx to Present at Upcoming Investor Conferences

GlobeNewswire November 13, 2017

argenx announces results of extraordinary shareholders' meeting 2017

GlobeNewswire November 7, 2017